Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-101 plus Pembrolizumab in RM HNSCC
NCT05668949Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tti-101 in head and neck squamous cell carcinoma (HNSCC), solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2025; status: withdrawn.
02
Drugs
tti-101
03
Conditions
head and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT05668949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668949.